Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study of ZD0473 and Doxil [liposomal doxorubicin] in Patients With Advanced Refractory Cancer

Trial Profile

A Phase I Study of ZD0473 and Doxil [liposomal doxorubicin] in Patients With Advanced Refractory Cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Jun 2008

At a glance

  • Drugs Doxorubicin liposomal; Picoplatin
  • Indications Ovarian cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 06 Jun 2008 Status changed rom recruiting to completed as reported in ASCO abstract.
    • 06 Jun 2008 Final results presented as ASCO 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top